Organon & Co. OGN | NYSE
After Hours
Next Earnings: Aug 04, 2025
Company Overview:
4.1 Year OGN Performance Metrics:
OGN Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
OGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
OGN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
OGN Dividends Info:
OGN Dividend History: Dates, Payments & Yield list
Below is a schedule of all OGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 05/12/2025 | 06/12/2025 | $0.020 | 9.87% | 0.79% | $10.07 |
| 02/24/2025 | 03/13/2025 | $0.280 | 7.43% | 7.49% | $14.96 |
| 11/12/2024 | 12/12/2024 | $0.280 | 7.19% | 7.3% | $15.35 |
| 08/16/2024 | 09/12/2024 | $0.280 | 5.5% | 5.52% | $20.29 |
| 05/10/2024 | 06/13/2024 | $0.280 | 5.48% | 5.46% | $20.51 |
| 02/23/2024 | 03/14/2024 | $0.280 | 6.05% | 6.1% | $18.36 |
| 11/10/2023 | 12/14/2023 | $0.280 | 10.07% | 8.74% | $12.82 |
| 08/17/2023 | 09/14/2023 | $0.280 | 4.99% | 5.66% | $19.79 |
| 05/12/2023 | 06/15/2023 | $0.280 | 5.37% | 5.35% | $20.92 |
| 02/24/2023 | 03/16/2023 | $0.280 | 4.38% | 5.16% | $21.72 |
| 11/10/2022 | 12/15/2022 | $0.280 | 4.53% | 3.96% | $28.28 |
| 08/12/2022 | 09/15/2022 | $0.280 | 3.61% | 3.9% | $28.75 |
| 05/13/2022 | 06/16/2022 | $0.280 | 3.21% | 3.41% | $32.81 |
| 02/25/2022 | 03/17/2022 | $0.280 | 2.24% | 3.26% | $34.34 |
| 11/19/2021 | 12/16/2021 | $0.280 | 1.79% | 3.69% | $30.33 |
| 08/20/2021 | 09/13/2021 | $0.280 | 0.84% | 3.31% | $33.83 |
Projected Future Returns & Dividends for OGN
Based on past 4.1-year performance, here are OGN growth metrics:
Share price CAGR of -25.99%
Dividend CAGR of -50.57%
Using OGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| OGN (DRIP) | OGN - No DRIP | |
|---|---|---|
| Current Price | $9.68 | $9.68 |
| Start Shares | 1,033.06 | 1,033.06 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,058.61 | 1,033.06 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $0.64 | $0.64 |
| Total Dividends | $165 | $163 |
| Final Value | $683 | $829 |
NOTE: Above numbers are our estimate based on OGN's Dividend and Price CAGR over past 4.1 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Organon & Co. (OGN) had its IPO on 2021-05-14, and is trader on NYSE stock exchange.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
OGN website: https://www.organon.com
